Table 2.
Number of Detected CTCs from 2 ml peripheral blood.
| Patient Group | Patients (n) | CTCs+ Patients (n) | CTC Mean±SD | Positive rate |
|---|---|---|---|---|
| AFP | ||||
| <20 | 17 | 8 | 1±2 | 47.1% |
| 20-100 | 5 | 3 | 1±1 | 60.0% |
| 100-400 | 5 | 2 | 1±1 | 40.0% |
| ≥400 | 15 | 12 | 3±2 | 80.0% |
| Tumor number | ||||
| Single | 25 | 15 | 1±2 | 60.0% |
| Multi | 17 | 12 | 2±2 | 70.6% |
| Tumor size (cm) | ||||
| <3 | 5 | 1 | 0±1 | 20.0% |
| 3-5 | 9 | 4 | 1±1 | 44.4% |
| ≥5 | 28 | 22 | 2±2 | 78.6% |
| Portal vein thrombus | ||||
| With | 9 | 9 | 4±2 | 100.0% |
| Without | 33 | 18 | 1±1 | 54.5% |
| TNM stagea | ||||
| Stage I | 16 | 6 | 1±1 | 37.5% |
| Stage II | 11 | 6 | 1±1 | 54.5% |
| Stage III | 12 | 10 | 3±2 | 83.3% |
| Stage IV | 3 | 3 | 4±2 | 100.0% |
| Total | 42 | 25 | 2±2 | 59.5% |
a. Sixth edition of UICC TNM staging system of HCC (2002).